GRAIL, a healthcare company specializing in early cancer detection, reported revenue of $125.6M for 2024, comprising $108.6M from screening revenue and $17.0M from development services. The company posted a net loss of $2.0B, which included a $1.4B goodwill and intangible impairment charge. The company maintained a strong cash position of $763.4M, consisting of $214.2M in cash equivalents and $549.2M in marketable securities.The company successfully completed a strategic restructuring in Q4 2024, implementing a 30% workforce reduction expected to generate annual cost savings of approximately $120M. GRAIL continues to advance its core multi-cancer early detection (MCED) business, with its primary product Galleri gaining traction in the market. The company has built a network of 13,000+ prescribers across the US and sold over 290,000 commercial tests through December 2024.Looking ahead, GRAIL is pursuing FDA approval...Show More

GRAIL, a healthcare company specializing in early cancer detection, reported revenue of $125.6M for 2024, comprising $108.6M from screening revenue and $17.0M from development services. The company posted a net loss of $2.0B, which included a $1.4B goodwill and intangible impairment charge. The company maintained a strong cash position of $763.4M, consisting of $214.2M in cash equivalents and $549.2M in marketable securities.The company successfully completed a strategic restructuring in Q4 2024, implementing a 30% workforce reduction expected to generate annual cost savings of approximately $120M. GRAIL continues to advance its core multi-cancer early detection (MCED) business, with its primary product Galleri gaining traction in the market. The company has built a network of 13,000+ prescribers across the US and sold over 290,000 commercial tests through December 2024.Looking ahead, GRAIL is pursuing FDA approval for Galleri, with a PMA submission planned for H1 2026. The company maintains strategic partnerships with healthcare systems and the UK NHS, while advancing its international expansion strategy. Following its June 2024 spin-off from Illumina, which retains a 13.3% stake, GRAIL operates with a focused approach on developing its MCED technology and expanding market presence.